Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial Post author: Post published:December 10, 2024 Post category:uncategorized A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). You Might Also Like Can AI outshine human experts in reviewing scientific papers? October 9, 2023 Rethinking community spaces and their impact on youth mental health December 1, 2025 UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas March 26, 2024
UC researchers open Phase 2 clinical trial to test new combination treatment for glioblastomas March 26, 2024